{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T07:49:33Z","timestamp":1775461773973,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00210-025-04717-4","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:48:48Z","timestamp":1765878528000},"page":"7631-7641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of fulvestrant and capecitabine as maintenance therapy in patients with HR\u2009+\/HER2\u2009\u2212\u2009metastatic breast cancer benefited from first-line chemotherapy"],"prefix":"10.1007","volume":"399","author":[{"given":"Qing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangyun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"issue":"12","key":"4717_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14715\/cmb\/2022.68.12.15","volume":"68","author":"H Azmi","year":"2022","unstructured":"Azmi H, Saif I, Nabil K, El Mzibri M, Boutayeb S, Lak R, Ennaji MME (2022) Human papilloma virus profiles in breast cancer in correlation with vitamin D. Cellular and Molecular Biology (Noisy-le-Grand, France) 68(12):79\u201383","journal-title":"Cell Mol Biol (Noisy-le-Grand, France)"},{"key":"4717_CR2","doi-asserted-by":"crossref","unstructured":"Cazzaniga ME, Capici S, Cordani N, Cogliati V, Pepe FF, Riva F, Cerrito MG (2022) Metronomic chemotherapy for metastatic breast cancer treatment: clinical and preclinical data between lights and shadows. J Clin Med (JCM) 11(16):4710(1\u201318)","DOI":"10.3390\/jcm11164710"},{"issue":"10","key":"4717_CR3","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1097\/CAD.0000000000000987","volume":"31","author":"A Di Federico","year":"2020","unstructured":"Di Federico A, Nuvola G, Sisi M, Lenzi B, Nobili E, Campana D (2020) Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible? Anticancer Drugs 31(10):1103\u20131105","journal-title":"Anticancer Drugs"},{"issue":"3","key":"4717_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14737167.2021.1848553","volume":"21","author":"V Diaby","year":"2020","unstructured":"Diaby V, Almutairi RD, Babcock A, Moussa RK, Ali A (2020) Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews. Expert Rev Pharmacoecon Outcomes Res 21(3):353\u2013364","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"4717_CR5","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3904\/kjim.2017.226","volume":"34","author":"MH Heo","year":"2019","unstructured":"Heo MH, Kim HK, Lee H, Kim JY, Ahn JS, Im YH, Park YH (2019) Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and\/or chemotherapy. Korean J Intern Med 34(5):1100\u20131106","journal-title":"Korean J Intern Med"},{"issue":"2","key":"4717_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12282-021-01303-3","volume":"29","author":"N Horisawa","year":"2022","unstructured":"Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Ozaki Y, Sugino K, Kataoka A, Kotani H, Yoshimura A, Hattori M, Sawaki M, Iwata H (2022) The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer 29(2):234\u2013241","journal-title":"Breast Cancer"},{"key":"4717_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cancergen.2022.09.007","volume":"268\u2013269","author":"W Jiawei","year":"2022","unstructured":"Jiawei W, Xiajun B, Tian S, Xuzheng G, Zhenwang Z (2022) Comprehensive analysis of PLKs expression and prognosis in breast cancer. Cancer Genet 268\u2013269:83\u201392","journal-title":"Cancer Genet"},{"issue":"34","key":"4717_CR8","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cort\u00e9s J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O\u2019Shaughnessy J, Rastogi P, monarchE Committee Members and Investigators (2020) Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol 38(34):3987\u20133998","journal-title":"J Clin Oncol"},{"issue":"7","key":"4717_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000529851","volume":"101","author":"Y Kanbayashi","year":"2023","unstructured":"Kanbayashi Y, Taguchi T, Ishikawa T, Otsuji E, Takayama K (2023) Risk factors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study. Oncology 101(7):407\u2013414","journal-title":"Oncology"},{"issue":"13","key":"4717_CR10","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2217\/fon-2020-0504","volume":"17","author":"C Kay","year":"2021","unstructured":"Kay C, Mart\u00ednez-P\u00e9rez C, Meehan J, Gray M, Webber V, Dixon JM, Turnbull AK (2021) Current trends in the treatment of HR+\/HER2+ breast cancer. Future Oncol 17(13):1665\u20131681","journal-title":"Future Oncol"},{"key":"4717_CR11","doi-asserted-by":"crossref","unstructured":"Knikman JE, Rosing H, Guchelaar HJ, Cats A, Beijnen JH (2020) A review of the bioanalytical methods for the quantitative determination of capecitabine and its metabolites in biological matrices. Biomed Chromatogr 34(1):e4732(1\u201312)","DOI":"10.1002\/bmc.4732"},{"issue":"5","key":"4717_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02356-y","volume":"41","author":"AM Knudsen","year":"2024","unstructured":"Knudsen AM, Modvig MW, Vogsen M, Kodahl AR (2024) Effect of capecitabine as monotherapy for HER2 normal metastatic breast cancer. Med Oncol 41(5):99","journal-title":"Med Oncol"},{"issue":"1\u20132","key":"4717_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000520236","volume":"45","author":"S Krajnak","year":"2022","unstructured":"Krajnak S, Battista MJ, Hasenburg A, Schmidt M (2022) Metronomic chemotherapy for metastatic breast cancer. Oncol Res Treat 45(1\u20132):12\u201317","journal-title":"Oncol Res Treat"},{"key":"4717_CR14","doi-asserted-by":"crossref","unstructured":"Llombart-Cussac A, P\u00e9rez-Garc\u00eda JM, Bellet M, Dalenc F, Gil-Gil M, Ru\u00edz-Borrego M, Gavil\u00e1 J, Sampayo-Cordero M, Aguirre E, Schmid P, Marm\u00e9 F, Di Cosimo S, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, Mart\u00ednez-de Due\u00f1as E, Amillano K, Malfettone A, Cort\u00e9s J; PARSIFAL Steering Committee and Trial Investigators (2021) Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer: a randomized clinical trial. JAMA Oncol 7(12):1791\u20131799","DOI":"10.1001\/jamaoncol.2021.4301"},{"key":"4717_CR15","doi-asserted-by":"crossref","unstructured":"Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano \u00c1, Garc\u00eda-S\u00e1enz JA, Torres R, de la Haba J, Garc\u00eda-Mart\u00ednez E, G\u00f3mez HL, Llombart A, Bofill JS, Baena-Ca\u00f1ada JM, Barnadas A, Calvo L, P\u00e9rez-Michel L, Ramos M, Fern\u00e1ndez I, Rodr\u00edguez-Lescure \u00c1, C\u00e1rdenas J, Vinholes J, Mart\u00ednez de Due\u00f1as E, Godes MJ, Segu\u00ed MA, Ant\u00f3n A, L\u00f3pez-\u00c1lvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Mart\u00edn M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group) (2020) Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003\u201311_CIBOMA\/2004\u201301). J Clin Oncol 38(3):203\u2013213","DOI":"10.1200\/JCO.19.00904"},{"issue":"8","key":"4717_CR16","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2217\/fon-2021-0668","volume":"18","author":"S Lopez-Tarruella","year":"2022","unstructured":"Lopez-Tarruella S, Echavarria I, Jerez Y, Herrero B, Gamez S, Martin M (2022) How we treat HR-positive, HER2-negative early breast cancer. Future Oncol 18(8):1003\u20131022","journal-title":"Future Oncol"},{"key":"4717_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/BCTT.S451617","volume":"16","author":"Q Ma","year":"2024","unstructured":"Ma Q, Liu YB, She T, Liu XL (2024) The role of Ki-67 in HR+\/HER2- breast cancer: a real-world study of 956 patients. Breast Cancer Targets Ther 16:117\u2013126","journal-title":"Breast Cancer Targets Ther"},{"issue":"22","key":"4717_CR18","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147\u20132159","journal-title":"N Engl J Med"},{"key":"4717_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115113","volume":"213","author":"C Molinelli","year":"2024","unstructured":"Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collov\u00e0 E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L (2024) The journey of patients affected by metastatic hormone receptor-positive\/HER2-negative breast cancer from CDK 4\/6 inhibitors to second-line treatment: a real-world analysis of 701 patients enrolled in the GIM14\/BIOMETA study. Eur J Cancer 213:115113","journal-title":"Eur J Cancer"},{"issue":"11","key":"4717_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nrclinonc.2015.131","volume":"12","author":"E Munzone","year":"2015","unstructured":"Munzone E, Colleoni M (2015) Clinical overview of metronomic chemotherapy in breast cancer. Nat Rev Clin Oncol 12(11):631\u2013644","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"4717_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.abd.2022.05.004","volume":"98","author":"ADAD Nascimento","year":"2023","unstructured":"Nascimento ADAD, Porto DM, Vidal AKL (2023) Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome - a literature review. An Bras Dermatol 98(3):302\u2013309","journal-title":"An Bras Dermatol"},{"issue":"11","key":"4717_CR22","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, Andr\u00e9 F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Huang Bartlett C, Turner NC (2018) The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov 8(11):1390\u20131403","journal-title":"Cancer Discov"},{"issue":"5","key":"4717_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D, Anthony A, Corrie P, Falk S, Finch-Jones M, Wasan H, Ross P, Wall L, Wadsley J, Evans JTR, Stocken D, Praseedom R, Ma YT, Davidson B, Neoptolemos JP, Iveson T, Raftery J, Zhu S, Cunningham D, Garden OJ, Stubbs C, Valle JW, Bridgewater J, BILCAP study group (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 20(5):663\u2013673","journal-title":"Lancet Oncol"},{"issue":"7","key":"4717_CR24","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","volume":"36","author":"L Provenzano","year":"2025","unstructured":"Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Miliziano D, Menichetti A, Ligorio F, Zurlo C, Griguolo G, Berton Giachetti PP, Faso V, Corti C, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, Vernieri C, PALMARES-2 Study Group (2025) Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative BC patients: results from the multicenter PALMARES-2 study. Ann Oncol 36(7):762\u2013774","journal-title":"Ann Oncol"},{"issue":"9","key":"4717_CR25","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdn165","volume":"19","author":"F Puglisi","year":"2008","unstructured":"Puglisi F, Cardellino GG, Crivellari D (2008) Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Ann Oncol 19(9):1541\u20131546","journal-title":"Ann Oncol"},{"issue":"3","key":"4717_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.clbc.2019.12.012","volume":"20","author":"N Rashad","year":"2020","unstructured":"Rashad N, Abdelhamid T, Shouman SA, Nassar H, Omran MA, El Desouky ED, Khaled H (2020) Capecitabine-based chemoendocrine combination as first-line treatment for metastatic hormone-positive metastatic breast cancer: phase 2 study. Clin Breast Cancer 20(3):228\u2013237","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"4717_CR27","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/annonc\/mdp447","volume":"21","author":"JFR Robertson","year":"2010","unstructured":"Robertson JFR, Steger GG, Neven P, Barni S, Gieseking F, Nol\u00e8 F, Pritchard KI, O\u2019Malley FP, Simon SD, Kaufman B, Petruzelka L (2010) Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Ann Oncol 21(6):1246\u20131253","journal-title":"Ann Oncol"},{"issue":"1","key":"4717_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11523-018-0587-9","volume":"14","author":"S Sammons","year":"2019","unstructured":"Sammons S, Kornblum NS, Blackwell KL (2019) Fulvestrant-based combination therapy for second-line treatment of hormone receptor-positive advanced breast cancer. Target Oncol 14(1):1\u201312","journal-title":"Target Oncol"},{"key":"4717_CR29","doi-asserted-by":"crossref","unstructured":"Santhosh A, Kumar A, Pramanik R, Gogia A, Prasad CP, Gupta I, Gupta N, Cheung WY, Pandey RM, Sharma A, Batra A (2022) Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). Trials 23(1):420(1\u201310)","DOI":"10.1186\/s13063-022-06353-2"},{"issue":"2","key":"4717_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/bcp.14723","volume":"87","author":"JJ Schneider","year":"2021","unstructured":"Schneider JJ, Galettis P, Martin JH (2021) Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine. Br J Clin Pharmacol 87(2):317\u2013325","journal-title":"Br J Clin Pharmacol"},{"key":"4717_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L (2016) RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 62:132\u2013137","journal-title":"Eur J Cancer"},{"key":"4717_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.breast.2016.06.024","volume":"31","author":"E Senkus","year":"2017","unstructured":"Senkus E, \u0141acko A (2017) Over-treatment in metastatic breast cancer. Breast 31:309\u2013317","journal-title":"Breast"},{"key":"4717_CR33","doi-asserted-by":"crossref","unstructured":"Shikata S, Murata T, Yoshida M, Hashiguchi H, Yoshii Y, Ogawa A, Watase C, Shiino S, Sugino H, Jimbo K, Maeshima A, Iwamoto E, Takayama S, Suto A (2023) Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer. Sci Rep 13(1):19669(1\u201311)","DOI":"10.1038\/s41598-023-47033-8"},{"issue":"1","key":"4717_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A (2020) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6(1):116\u2013124","journal-title":"JAMA Oncol"},{"issue":"5 Suppl 10","key":"4717_CR35","first-page":"72","volume":"27","author":"A Sobrero","year":"2000","unstructured":"Sobrero A, Guglielmi A, Grossi F, Puglisi F, Aschele C (2000) Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 27(5 Suppl 10):72\u201377","journal-title":"Semin Oncol"},{"issue":"20","key":"4717_CR36","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Andr\u00e9 F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M (2018) Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 379(20):1926\u20131936","journal-title":"N Engl J Med"},{"issue":"2","key":"4717_CR37","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/1078155221989420","volume":"28","author":"MB Visacri","year":"2022","unstructured":"Visacri MB, Duarte NC, Lima TM, de Souza RN, Cobaxo TS, Teixeira JC, Barbosa CR, Dias LP, Tavares MG, Pincinato EC, Lima CS, Moriel P (2022) Adverse reactions and adherence to capecitabine: a prospective study in patients with gastrointestinal cancer. J Oncol Pharm Pract 28(2):326\u2013336","journal-title":"J Oncol Pharm Pract"},{"key":"4717_CR38","doi-asserted-by":"crossref","unstructured":"Zhang J, Qin Z, So TH, Chang TY, Yang S, Chen H, Yeung WF, Chung KF, Chan PY, Huang Y, Xu S, Chiang CY, Lao L, Zhang ZJ (2023) Acupuncture for chemotherapy-associated insomnia in breast cancer patients: an assessor-participant blinded, randomized, sham-controlled trial. Breast Cancer Res 25(1):49(1\u201315)","DOI":"10.1186\/s13058-023-01645-0"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04717-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04717-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04717-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T06:52:32Z","timestamp":1775458352000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04717-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4717"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04717-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Third Hospital of Nanchang City (Approval No. K-ky2022005); all experiments were performed in accordance with relevant guidelines and regulations, such as the Declaration of Helsinki, and the patients signed the informed consent form and agreed to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}